SCHEMBL4176965

SCHEMBL4176965

O=C1CCCN1CCCNc1ncccc1-c1nnc(N(Cc2ccccc2)C2=COCO2)o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MALT1 Q9UDY8 1/20 0.39
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.37
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
HSD17B10 Q99714 1/20 0.37
BTK Q06187 1/20 0.37
MKNK1 Q9BUB5 2/20 0.36
MKNK2 Q9HBH9 2/20 0.36
AKT1 P31749 1/20 0.36
ADORA1 P30542 1/20 0.36
TYRO3 Q06418 2/20 0.36
CASP1 P29466 1/20 0.35
CASP3 P42574 1/20 0.35
CASP8 Q14790 1/20 0.35
CD274 Q9NZQ7 2/20 0.35
MEN1 O00255 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35
KDR P35968 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4180740 0.76 TUBB4A (0.51) ALDH1A1HPGDKDM4EKDRMAPT
SCHEMBL4179147 0.76 TUBB4A (0.50) ALDH1A1HPGDKDM4ELMNAKDR
SCHEMBL4181034 0.75 TUBB4A (0.44) ALDH1A1HPGDKDM4EKDR
SCHEMBL4174430 0.75 TUBB4A (0.46) ALDH1A1HPGDKDM4ELMNAHSD17B10
SCHEMBL4175666 0.75 MALT1 (0.34) MALT1ALDH1A1HPGDKDM4ELMNA
SCHEMBL4168430 0.74 TUBB4A (0.53) ALDH1A1HPGDKDM4EKDR
SCHEMBL4177070 0.74 TUBB4A (0.53) ALDH1A1HPGDKDM4EKDRNPC1
SCHEMBL4185065 0.74 TUBB4A (0.41) ALDH1A1HPGDKDM4EBTKKDR
SCHEMBL4185094 0.74 TUBB4A (0.47) KDR
SCHEMBL4181460 0.74 TUBB4A (0.46) ALDH1A1HPGDKDM4EKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 US disclosed
WO-2005004818-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TP53, MCL1, VHL MALT1 544/4885ALDH1A1 535/4885HPGD 95/4885
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents TP53, MCL1, VHL MALT1 544/4885ALDH1A1 535/4885HPGD 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.